Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who decide whether treatment is appropriate. Compounded medications are prepared by licensed U.S. pharmacies for individual patients and are not reviewed by the FDA for safety or effectiveness.
Sources
- U.S. Food and Drug Administration. Foundayo (orforglipron) tablets, prescribing information (revised July 2026).
- U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (April 1, 2026).
- Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806.
- Aronne LJ, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026;32:2679-2687.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information (revised August 2026).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets, prescribing information (revised June 2026).
- Drugs@FDA. NDA 218316, Wegovy tablets, approval history.
- Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393:1077-1087.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36.
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026.
- ClinicalTrials.gov. Registered studies of orforglipron (searched October 19, 2026).
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026).
- CNBC. FDA approves Eli Lilly's GLP-1 pill Foundayo for obesity (April 1, 2026).
- CNBC. First GLP-1 pill for obesity launches in the U.S. (January 5, 2026).
- CNBC. Zepbound pen with one-month doses launches (February 23, 2026).






